Retatrutide Price: $0.42 per 100 mcg on a 30 mg Vial

Two vials, two prices, two rates. The last column is the one most price pages leave out: milligrams per dollar, which is the same comparison read backwards.

Divide and the ranking flips. $49.50 ÷ 10 mg is $4.95 per mg. $125.00 ÷ 30 mg is $4.1667, which rounds to $4.17. The larger vial carries the higher sticker and the lower rate, by $0.78 per mg, or 15.8%.

Read the other way, $1.00 buys 0.202 mg from the small vial and 0.240 mg from the large one, which is 18.8% more material. The two percentages differ because they are reciprocals of each other, not because one of them is wrong. Quote whichever fits the decision in front of you, but quote only one.

A vial price answers exactly one question: what leaves your account. It says nothing about how much compound arrived, and nothing about what a single draw off the reconstituted vial is worth. Two further divisions fix that.

Cost per milligram divides the discounted price by the labelled strength. It is supplier-comparable, and it is the only figure worth putting next to another storefront's number.

Cost per research unit divides the same price by the graduations you can actually draw, which depends on the diluent volume you pick. That makes it bench-comparable rather than supplier-comparable, and it moves when you change your mind about the volume.

Watch what the first two rows do. The same vial, made up at two different volumes, produces two different costs per unit, $0.25 and $0.50, while the cost per 100 mcg does not move at all. Cost per unit only compares across vials when the concentrations match.

At a matched 10 mg/mL the comparison is clean: $0.50 per unit from the small vial against $0.42 from the large one. Same graduation, same mass in it, different price. Our syringe measurement guide covers the unit conversion, and the reconstitution calculator will run any volume you enter.

The query assumes a covered product with a cash fallback. Retatrutide has neither, and the reason is structural rather than a matter of plan design.

Coverage runs through an approved product. An approved drug carries a marketing authorisation, a national drug code, a labelled indication and a place on a formulary. Retatrutide has none of those, so no plan can list it, no pharmacy can adjudicate a claim against it, and there is no prior authorisation to request. The FDA approved drug database is searchable, and no retatrutide entry appears in it.

There is also no dispensing event. Research material is sold as a laboratory reagent against an order, not dispensed against a prescription, so there would be no claim to submit even if a plan wanted to pay one. That is why every retatrutide cost you see quoted anywhere is a cash price on a research listing.

Approved incretin products sit in a different category. Semaglutide and tirzepatide hold authorisations, occupy formulary positions and can be covered subject to plan terms, which our GLP-1 medications overview goes through. Be precise about this when comparing retatrutide cost and price against a copay: those are two different kinds of transaction, not two prices for the same thing.

The published bulk tiers take 3% off at three units, 5% at five and 10% at ten, calculated from the list price rather than from the discounted price. Run the ladder and the answer is not close.

The best rung on that ladder, ten vials at $7.50 per mg, is still 80% more per milligram than one vial bought with the code at $4.17. A 10% discount cannot catch a 50% one, and buying nine extra vials to chase it is an expensive way to lose the comparison.

What the ladder cannot tell you is whether a checkout applies a tier and the code together. That is a cart rule rather than a published one, so treat stacking as something to observe on the payment screen, not something to plan an order around. The retatrutide coupon page works through what the numbers look like if they do stack.

Free shipping applies over $250. With the code active that line sits further away than it looks, because the code halves the number the threshold is measured against.

• 1 × R-30 with the code is $125.00, well under the line.
• 1 × R-30 plus 1 × R-10 is $174.50, still under.
• 2 × R-30 is $250.00 exactly, which is at the threshold rather than over it.
• 3 × R-30 is $375.00 and clears it.

Whether the threshold reads the subtotal before or after the code is a checkout rule, and the checkout is the only place that can settle it. If it reads the pre-code subtotal, a single R-30 at $250.00 list is already sitting on the line.

Either way, shipping is a fixed cost, so it divides by strength rather than scaling with it. Take a flat $12.00 charge as an example: it adds $1.20 per mg to a 10 mg vial and $0.40 per mg to a 30 mg vial. Fixed charges always fall hardest on the smaller vial, which is why a cart total rather than a product price is the honest input to any per-mg comparison.

Cost per mg quietly assumes every labelled milligram reaches a syringe. It does not. Two effects sit between the label and the bench, and both raise the real rate.

Residual volume. A small amount of solution stays in the vial shoulder and the needle hub after the final draw. Assume 0.05 mL is unrecoverable. On a 30 mg vial made up to 3 mL that is 1.7% of the volume, or 0.5 mg, and the effective rate moves from $4.17 to $4.24 per mg. On a 10 mg vial at 2 mL the same 0.05 mL is 2.5%, or 0.25 mg, and the rate moves from $4.95 to $5.08.

The gap between the two vials widens slightly as a result, from 15.8% to 16.5%, for the same reason a flat shipping charge widens it. A fixed loss divided by a larger denominator costs less per milligram.

Labelled mass against peptide mass. Lyophilised peptide is weighed as a salt, so some of the mass in the vial is counterion and residual solvent rather than peptide. How much is a question for the certificate covering your batch, not for a price page. Whatever the figure turns out to be, it applies to both vials, so it shifts both rates without changing which one is lower. Our peptide calculator guide explains why the arithmetic has to accept a labelled figure it cannot verify by itself.

A rate per milligram measures one thing, and it is worth naming what it leaves out.

• Purity. The certificate covering your batch settles that. Ascension publishes two per batch: Kovera Labs for batches 03-05260628 and 43-05260628, tested 26 May 2026, and MZ Biolabs for batches 03-01260229 and 43-01260229, tested 6 February 2026. Match the code on the certificate to the code printed on your vial before you trust the milligram figure the whole calculation rests on.
• Approval. Retatrutide is investigational. The Phase 2 results in the New England Journal of Medicine reported about 24% mean weight reduction at 48 weeks on the 12 mg arm, and the Phase 3 TRIUMPH programme is still running. Trial data is not authorisation, and research material is not a medicine.
• Recourse. A cheap vial from a seller with no written refund terms is not cheap, it is risk you have not priced. Our sourcing checklist covers the checks a price cannot make on your behalf.

Price is the easiest thing to compare and the least informative thing to compare on its own. The order that works is certificate first, dispatch second, arithmetic third, because only the third step has a number in it and the first two decide whether that number means anything.